{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable as only a single participant was analyzed. Median value presented here is the actual duration of response for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"2.1"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"2.1","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).","dispersionType":"Full Range","groups":[{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single intravenous (IV) infusion of GSK3377794.","id":"OG000","title":"GSK3377794"},{"description":"Eligible participants underwent leukapheresis to manufacture engineered T-cells. Participants then underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single IV infusion of GSK3377794 in combination with pembrolizumab 200 milligrams (mg) administered as an IV infusion every 3 weeks up to Week 108.","id":"OG001","title":"GSK3377794+Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Modified ITT Population. Only those participants with a confirmed response per IMWG 2016 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 108 weeks","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}